Barclays PLC Cytom X Therapeutics, Inc. Call Options Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTMX
# of Institutions
70Shares Held
50.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$6.95 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.65 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.59 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.28 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$2.76 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $58.7M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...